Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Sponsor
Henan Cancer Hospital
Study ID
NCT03942068
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • albumin-bound paclitaxel — DRUG
    Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
  • Apatinib — DRUG
    a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)

Study Details

The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

Key Dates

Start date
Sep 1, 2019
Status verified
May 2019
Primary completion
Sep 1, 2020
Completion
Dec 30, 2020

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: albumin-bound paclitaxel+apatinib
    albumin-bound paclitaxel:260mg/m2，q3w，d1 apatinib:500mg，qd，po

Primary Outcome Measure

ORR [ Time Frame: Baseline up to cycle 4 (assessed at Baseline, at the time of pre-surgery)up to approximately 12 months ]

Related Studies